SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers received their first shot of the vaccine] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By | 2016-03-24T04:54:28+00:00 August 27th, 2009|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR

[REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers received their first shot of the vaccine] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By | 2016-03-24T04:55:33+00:00 August 27th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers have received their first shot of the vaccine] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By | 2016-03-24T04:57:26+00:00 August 27th, 2009|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1

[SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers have received their first shot of the vaccine] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By | 2016-03-24T04:59:04+00:00 August 27th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1) BEIJING, July 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, today announced that it has initiated dosing today in its clinical trial of various Panflu vaccine candidates for pandemic influenza A (H1N1). Results are expected in September 2009.] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By | 2016-03-24T05:00:31+00:00 August 27th, 2009|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Initiates Dosing in Human Clinical Trial of

[Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1) BEIJING, July 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, today announced that it has initiated dosing today in its clinical trial of various Panflu vaccine candidates for pandemic influenza A (H1N1). Results are expected in September 2009.] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By | 2016-03-24T05:01:46+00:00 August 27th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Adjourns 2008 Annual General Meeting BEIJING, July 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that its Annual General Meeting originally scheduled for July 16, 2009 has been adjourned to July 30, 2009. At the July 16, 2009 Annual General Meeting, the required quorum of a majority] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By | 2016-03-24T05:03:19+00:00 August 27th, 2009|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2009 FINANCIAL RESULTS Second Quarter 2009 Revenue Increased 40.6% to Approximately $13.2 Million and Net Income Increased 119.3% to Approximately $3.9 Million with EPS of $0.17 Gross Margins Improved 1630-Basis Points to 73.5% over Q2 2008 Press Release Source: Biostar Pharmaceuticals, Inc. On Friday August 14, 2009, 7:30 am EDT BSPM News ; XIANYANG,] [BIOSTAR PHARMACEUTICALS, INC. TO HOST FISCAL YEAR 2009 SECOND QUARTER EARNINGS CONFERENCE CALL ON FRIDAY, AUGUST 14, 2009 AT 10:30 A.M. EDT Press Release Source: Biostar Pharmaceuticals, Inc. On Wednesday August 12, 2009, 7:30 am EDT BSPM News ; XIANYANG, China, Aug. 12 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: http://www.viavid.net http://viavid.net/dce.aspx?sid=00006906 http://www.microsoft.com/windows/windowsmedia/en/download/default.asp This call is being web cast]

By | 2016-03-03T15:50:50+00:00 August 18th, 2009|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2009 FINANCIAL

[BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2009 FINANCIAL RESULTS Second Quarter 2009 Revenue Increased 40.6% to Approximately $13.2 Million and Net Income Increased 119.3% to Approximately $3.9 Million with EPS of $0.17 Gross Margins Improved 1630-Basis Points to 73.5% over Q2 2008 Press Release Source: Biostar Pharmaceuticals, Inc. On Friday August 14, 2009, 7:30 am EDT BSPM News ; XIANYANG,] [BIOSTAR PHARMACEUTICALS, INC. TO HOST FISCAL YEAR 2009 SECOND QUARTER EARNINGS CONFERENCE CALL ON FRIDAY, AUGUST 14, 2009 AT 10:30 A.M. EDT Press Release Source: Biostar Pharmaceuticals, Inc. On Wednesday August 12, 2009, 7:30 am EDT BSPM News ; XIANYANG, China, Aug. 12 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: http://www.viavid.net http://viavid.net/dce.aspx?sid=00006906 http://www.microsoft.com/windows/windowsmedia/en/download/default.asp This call is being web cast]

By | 2016-03-03T15:52:04+00:00 August 18th, 2009|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI’AN,

[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA – August 14, 2009 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS § Revenues increased 39.4% year-over-year to $6.2 million § Gross margin improved to 52.6% from 51.6% in the second quarter of 2008 § Income from operations increased by 37.6% year-over-year to $1.7 million § Began]

By | 2016-03-01T07:26:43+00:00 August 14th, 2009|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar